Labetuzumab govitecan (ADC)

Catalog No.

DHC21097

Description

Labetuzumab govitecan is an ADC consisting of a CEACAM5-directed antibody and SN38 used for the study of various cancers including colorectal cancer.

Species reactivity

Human

Clonality

Monoclonal

Target

CEACAM5

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Purification

Purified by Ion Exchange Chromatography.

Applications

Research Grade Biosimilar

Form

Liquid

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

IMMU130, hMN-14-SN-38

Clone ID

Labetuzumab govitecan

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer., PMID:33199493

Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan., PMID:30822636

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)., PMID:29079710

Labetuzumab govitecan in metastatic colorectal cancer., PMID:28844817

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer., PMID:28817371

Document Download

Labetuzumab govitecan (ADC).pdf